Jeffrey D Seidman, M.D. Expert Witness
Curriculum Vitae

Cancer Pathologist- Delayed Diagnosis

Contact this Expert Witness

  • Phone: 301-455-1610
  • Cell: 301-455-1610
  • Fax: 301-926-4251

Specialties & Experience of this Expert Witness

General Specialties:

Pathology and Anatomic Pathology

Keywords/Search Terms:

gynecological cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, ovary, ovaries, peritoneum, uterine cancer, endometrial cancer, endometrium, uterus, cervical cancer, cervix, diagnostic delay, pathology, delayed diagnosis

Education:

M.D., SUNY Downstate Health Sciences University; B.S., Tufts University

Years in Practice:

31

Additional Information

Dr. Seidman is a board-certified anatomic pathologist. His main area of expertise is gynecological cancers. As an expert witness over the past 25 years, he has reviewed medical malpractice cases involving ovarian, fallopian tube, endometrial and cervical cancers, in addition to breast cancer, urologic cancers and gastrointestinal cancers. Dr. Seidman earned his medical degree at State University of New York Downstate Health Sciences University in 1987 and trained in anatomic pathology at Georgetown University, University of Maryland Hospital, and the Armed Forces Institute of Pathology. He was Director of Gynecological Pathology at the Washington Hospital Center in Washington, D.C. from 1995 through 2013. In 2013 he joined the Office of In Vitro Diagnostics and Radiological Health at the Food and Drug Administration where he was a Medical Officer in the Division of Molecular Genetics and Pathology in the Center for Devices and Radiological Health until 2022. He has authored or coauthored 92 original research papers, 18 book chapters, and 17 review articles, editorials, and commentaries. He is a coauthor of the 2014 World Health Organization Classification of Tumours of Female Reproductive Organs, and is a coauthor of the 2017 book, Differential Diagnoses in Surgical Pathology: Gynecologic Tract, with a newly published second edition in 2024. He has been on the Editorial Board of the International Journal of Gynecological Pathology for over 25 years. At the FDA, he was the lead clinical reviewer for the 2016 Ovarian Cancer Screening Safety Communication Team which was awarded the Lireka P. Joseph Award for Excellence in Public Health Communication or Education.